PBAC's latest decision on Tiotropium with olodaterol: Recommended (2024). Considered for Treatment of chronic obstructive pulmonary disease (COPD) in patients with persistent symptoms despite regular bronchodilator treatment with a long-acting muscarinic antagonist (LAMA) or long-acting beta 2 agonist (LABA), or in patients stabilised on a combination of LAMA and LABA.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2020
Submissions
2
2020 → 2024
Eligible population
Adults with chronic obstructive pulmonary disease and persistent symptoms despite regular bronchodilator treatment with a LAMA or LABA, or stabilised on combination LAMA/LABA therapy.
Therapy area
Respiratory
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
2 x single packs of tiotropium with olodaterol
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as 1 x double pack provides no incremental efficacy or toxicity benefit over 2 x single packs.